Selected research
Market Analysis & Forecast
Global Carrier Screening Tests Market Analysis and Forecast 2026-2032
Market perspective
The global Carrier Screening Tests market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Carrier Screening Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Carrier Screening Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Carrier Screening Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Carrier Screening Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Carrier Screening Tests include Thermo Fisher Scientific, Eurofins Scientific, Illumina, Invitae, MedGenome, Myriad Genetics, Roche, Natera and OPKO Health, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Carrier Screening Tests, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Carrier Screening Tests, also provides the revenue of main regions and countries. Of the upcoming market potential for Carrier Screening Tests, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Carrier Screening Tests revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Carrier Screening Tests market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Carrier Screening Tests revenue, projected growth trends, production technology, application and end-user industry.
Carrier Screening Tests Segment by Company
Thermo Fisher Scientific
Eurofins Scientific
Illumina
Invitae
MedGenome
Myriad Genetics
Roche
Natera
OPKO Health
23andMe
bioMérieux
EKF Diagnostics
Gene by Gene (myDNA)
Fulgent Genetics
NxGen MDx
Sonic Genetics
My Baby
AncestryDNA
DiaSorin
Grifols
BGI Genomics
Chigene
Jiajian Medical Testing
Genesky
Berry Genomics
Weihansi Biomedical Technology
Annaroad
Carrier Screening Tests Segment by Type
NGS
Whole Exome Sequencing
Others
Carrier Screening Tests Segment by Application
Couple
Individual
Carrier Screening Tests Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Carrier Screening Tests market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Carrier Screening Tests and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Carrier Screening Tests.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Carrier Screening Tests in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Carrier Screening Tests company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Carrier Screening Tests revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- NGS
- Whole Exome Sequencing
- Others
Applications
- Couple
- Individual
Companies covered
- Thermo Fisher Scientific
- Eurofins Scientific
- Illumina
- Invitae
- MedGenome
- Myriad Genetics
- Roche
- Natera
- OPKO Health
- 23andMe
- bioMérieux
- EKF Diagnostics
- Gene by Gene (myDNA)
- Fulgent Genetics
- NxGen MDx
- Sonic Genetics
- My Baby
- AncestryDNA
- DiaSorin
- Grifols
- BGI Genomics
- Chigene
- Jiajian Medical Testing
- Genesky
- Berry Genomics
- Weihansi Biomedical Technology
- Annaroad
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Carrier Screening Tests Market by Type
- 1.2.1 Global Carrier Screening Tests Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 NGS
- 1.2.3 Whole Exome Sequencing
- 1.2.4 Others
- 1.3 Carrier Screening Tests Market by Application
- 1.3.1 Global Carrier Screening Tests Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Couple
- 1.3.3 Individual
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Carrier Screening Tests Market Dynamics
- 2.1 Carrier Screening Tests Industry Trends
- 2.2 Carrier Screening Tests Industry Drivers
- 2.3 Carrier Screening Tests Industry Opportunities and Challenges
- 2.4 Carrier Screening Tests Industry Restraints
3 Global Growth Perspective
- 3.1 Global Carrier Screening Tests Market Perspective (2021-2032)
- 3.2 Global Carrier Screening Tests Growth Trends by Region
- 3.2.1 Global Carrier Screening Tests Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Carrier Screening Tests Market Size by Region (2021-2026)
- 3.2.3 Global Carrier Screening Tests Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Carrier Screening Tests Revenue by Players
- 4.1.1 Global Carrier Screening Tests Revenue by Players (2021-2026)
- 4.1.2 Global Carrier Screening Tests Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Carrier Screening Tests Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Carrier Screening Tests Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Carrier Screening Tests Key Players Headquarters & Area Served
- 4.4 Global Carrier Screening Tests Players, Product Type & Application
- 4.5 Global Carrier Screening Tests Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Carrier Screening Tests Market CR5 and HHI
- 4.6.3 2025 Carrier Screening Tests Tier 1, Tier 2, and Tier 3
5 Carrier Screening Tests Market Size by Type
- 5.1 Global Carrier Screening Tests Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Carrier Screening Tests Revenue by Type (2021-2032)
- 5.3 Global Carrier Screening Tests Revenue Market Share by Type (2021-2032)
6 Carrier Screening Tests Market Size by Application
- 6.1 Global Carrier Screening Tests Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Carrier Screening Tests Revenue by Application (2021-2032)
- 6.3 Global Carrier Screening Tests Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Thermo Fisher Scientific
- 7.1.1 Thermo Fisher Scientific Company Information
- 7.1.2 Thermo Fisher Scientific Business Overview
- 7.1.3 Thermo Fisher Scientific Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.1.4 Thermo Fisher Scientific Carrier Screening Tests Product Portfolio
- 7.1.5 Thermo Fisher Scientific Recent Developments
- 7.2 Eurofins Scientific
- 7.2.1 Eurofins Scientific Company Information
- 7.2.2 Eurofins Scientific Business Overview
- 7.2.3 Eurofins Scientific Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.2.4 Eurofins Scientific Carrier Screening Tests Product Portfolio
- 7.2.5 Eurofins Scientific Recent Developments
- 7.3 Illumina
- 7.3.1 Illumina Company Information
- 7.3.2 Illumina Business Overview
- 7.3.3 Illumina Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.3.4 Illumina Carrier Screening Tests Product Portfolio
- 7.3.5 Illumina Recent Developments
- 7.4 Invitae
- 7.4.1 Invitae Company Information
- 7.4.2 Invitae Business Overview
- 7.4.3 Invitae Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.4.4 Invitae Carrier Screening Tests Product Portfolio
- 7.4.5 Invitae Recent Developments
- 7.5 MedGenome
- 7.5.1 MedGenome Company Information
- 7.5.2 MedGenome Business Overview
- 7.5.3 MedGenome Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.5.4 MedGenome Carrier Screening Tests Product Portfolio
- 7.5.5 MedGenome Recent Developments
- 7.6 Myriad Genetics
- 7.6.1 Myriad Genetics Company Information
- 7.6.2 Myriad Genetics Business Overview
- 7.6.3 Myriad Genetics Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.6.4 Myriad Genetics Carrier Screening Tests Product Portfolio
- 7.6.5 Myriad Genetics Recent Developments
- 7.7 Roche
- 7.7.1 Roche Company Information
- 7.7.2 Roche Business Overview
- 7.7.3 Roche Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.7.4 Roche Carrier Screening Tests Product Portfolio
- 7.7.5 Roche Recent Developments
- 7.8 Natera
- 7.8.1 Natera Company Information
- 7.8.2 Natera Business Overview
- 7.8.3 Natera Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.8.4 Natera Carrier Screening Tests Product Portfolio
- 7.8.5 Natera Recent Developments
- 7.9 OPKO Health
- 7.9.1 OPKO Health Company Information
- 7.9.2 OPKO Health Business Overview
- 7.9.3 OPKO Health Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.9.4 OPKO Health Carrier Screening Tests Product Portfolio
- 7.9.5 OPKO Health Recent Developments
- 7.10 23andMe
- 7.10.1 23andMe Company Information
- 7.10.2 23andMe Business Overview
- 7.10.3 23andMe Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.10.4 23andMe Carrier Screening Tests Product Portfolio
- 7.10.5 23andMe Recent Developments
- 7.11 bioMérieux
- 7.11.1 bioMérieux Company Information
- 7.11.2 bioMérieux Business Overview
- 7.11.3 bioMérieux Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.11.4 bioMérieux Carrier Screening Tests Product Portfolio
- 7.11.5 bioMérieux Recent Developments
- 7.12 EKF Diagnostics
- 7.12.1 EKF Diagnostics Company Information
- 7.12.2 EKF Diagnostics Business Overview
- 7.12.3 EKF Diagnostics Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.12.4 EKF Diagnostics Carrier Screening Tests Product Portfolio
- 7.12.5 EKF Diagnostics Recent Developments
- 7.13 Gene by Gene (myDNA)
- 7.13.1 Gene by Gene (myDNA) Company Information
- 7.13.2 Gene by Gene (myDNA) Business Overview
- 7.13.3 Gene by Gene (myDNA) Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.13.4 Gene by Gene (myDNA) Carrier Screening Tests Product Portfolio
- 7.13.5 Gene by Gene (myDNA) Recent Developments
- 7.14 Fulgent Genetics
- 7.14.1 Fulgent Genetics Company Information
- 7.14.2 Fulgent Genetics Business Overview
- 7.14.3 Fulgent Genetics Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.14.4 Fulgent Genetics Carrier Screening Tests Product Portfolio
- 7.14.5 Fulgent Genetics Recent Developments
- 7.15 NxGen MDx
- 7.15.1 NxGen MDx Company Information
- 7.15.2 NxGen MDx Business Overview
- 7.15.3 NxGen MDx Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.15.4 NxGen MDx Carrier Screening Tests Product Portfolio
- 7.15.5 NxGen MDx Recent Developments
- 7.16 Sonic Genetics
- 7.16.1 Sonic Genetics Company Information
- 7.16.2 Sonic Genetics Business Overview
- 7.16.3 Sonic Genetics Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.16.4 Sonic Genetics Carrier Screening Tests Product Portfolio
- 7.16.5 Sonic Genetics Recent Developments
- 7.17 My Baby
- 7.17.1 My Baby Company Information
- 7.17.2 My Baby Business Overview
- 7.17.3 My Baby Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.17.4 My Baby Carrier Screening Tests Product Portfolio
- 7.17.5 My Baby Recent Developments
- 7.18 AncestryDNA
- 7.18.1 AncestryDNA Company Information
- 7.18.2 AncestryDNA Business Overview
- 7.18.3 AncestryDNA Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.18.4 AncestryDNA Carrier Screening Tests Product Portfolio
- 7.18.5 AncestryDNA Recent Developments
- 7.19 DiaSorin
- 7.19.1 DiaSorin Company Information
- 7.19.2 DiaSorin Business Overview
- 7.19.3 DiaSorin Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.19.4 DiaSorin Carrier Screening Tests Product Portfolio
- 7.19.5 DiaSorin Recent Developments
- 7.20 Grifols
- 7.20.1 Grifols Company Information
- 7.20.2 Grifols Business Overview
- 7.20.3 Grifols Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.20.4 Grifols Carrier Screening Tests Product Portfolio
- 7.20.5 Grifols Recent Developments
- 7.21 BGI Genomics
- 7.21.1 BGI Genomics Company Information
- 7.21.2 BGI Genomics Business Overview
- 7.21.3 BGI Genomics Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.21.4 BGI Genomics Carrier Screening Tests Product Portfolio
- 7.21.5 BGI Genomics Recent Developments
- 7.22 Chigene
- 7.22.1 Chigene Company Information
- 7.22.2 Chigene Business Overview
- 7.22.3 Chigene Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.22.4 Chigene Carrier Screening Tests Product Portfolio
- 7.22.5 Chigene Recent Developments
- 7.23 Jiajian Medical Testing
- 7.23.1 Jiajian Medical Testing Company Information
- 7.23.2 Jiajian Medical Testing Business Overview
- 7.23.3 Jiajian Medical Testing Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.23.4 Jiajian Medical Testing Carrier Screening Tests Product Portfolio
- 7.23.5 Jiajian Medical Testing Recent Developments
- 7.24 Genesky
- 7.24.1 Genesky Company Information
- 7.24.2 Genesky Business Overview
- 7.24.3 Genesky Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.24.4 Genesky Carrier Screening Tests Product Portfolio
- 7.24.5 Genesky Recent Developments
- 7.25 Berry Genomics
- 7.25.1 Berry Genomics Company Information
- 7.25.2 Berry Genomics Business Overview
- 7.25.3 Berry Genomics Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.25.4 Berry Genomics Carrier Screening Tests Product Portfolio
- 7.25.5 Berry Genomics Recent Developments
- 7.26 Weihansi Biomedical Technology
- 7.26.1 Weihansi Biomedical Technology Company Information
- 7.26.2 Weihansi Biomedical Technology Business Overview
- 7.26.3 Weihansi Biomedical Technology Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.26.4 Weihansi Biomedical Technology Carrier Screening Tests Product Portfolio
- 7.26.5 Weihansi Biomedical Technology Recent Developments
- 7.27 Annaroad
- 7.27.1 Annaroad Company Information
- 7.27.2 Annaroad Business Overview
- 7.27.3 Annaroad Carrier Screening Tests Revenue and Gross Margin (2021-2026)
- 7.27.4 Annaroad Carrier Screening Tests Product Portfolio
- 7.27.5 Annaroad Recent Developments
8 North America
- 8.1 North America Carrier Screening Tests Revenue (2021-2032)
- 8.2 North America Carrier Screening Tests Revenue by Type (2021-2032)
- 8.2.1 North America Carrier Screening Tests Revenue by Type (2021-2026)
- 8.2.2 North America Carrier Screening Tests Revenue by Type (2027-2032)
- 8.3 North America Carrier Screening Tests Revenue Share by Type (2021-2032)
- 8.4 North America Carrier Screening Tests Revenue by Application (2021-2032)
- 8.4.1 North America Carrier Screening Tests Revenue by Application (2021-2026)
- 8.4.2 North America Carrier Screening Tests Revenue by Application (2027-2032)
- 8.5 North America Carrier Screening Tests Revenue Share by Application (2021-2032)
- 8.6 North America Carrier Screening Tests Revenue by Country
- 8.6.1 North America Carrier Screening Tests Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Carrier Screening Tests Revenue by Country (2021-2026)
- 8.6.3 North America Carrier Screening Tests Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Carrier Screening Tests Revenue (2021-2032)
- 9.2 Europe Carrier Screening Tests Revenue by Type (2021-2032)
- 9.2.1 Europe Carrier Screening Tests Revenue by Type (2021-2026)
- 9.2.2 Europe Carrier Screening Tests Revenue by Type (2027-2032)
- 9.3 Europe Carrier Screening Tests Revenue Share by Type (2021-2032)
- 9.4 Europe Carrier Screening Tests Revenue by Application (2021-2032)
- 9.4.1 Europe Carrier Screening Tests Revenue by Application (2021-2026)
- 9.4.2 Europe Carrier Screening Tests Revenue by Application (2027-2032)
- 9.5 Europe Carrier Screening Tests Revenue Share by Application (2021-2032)
- 9.6 Europe Carrier Screening Tests Revenue by Country
- 9.6.1 Europe Carrier Screening Tests Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Carrier Screening Tests Revenue by Country (2021-2026)
- 9.6.3 Europe Carrier Screening Tests Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Carrier Screening Tests Revenue (2021-2032)
- 10.2 China Carrier Screening Tests Revenue by Type (2021-2032)
- 10.2.1 China Carrier Screening Tests Revenue by Type (2021-2026)
- 10.2.2 China Carrier Screening Tests Revenue by Type (2027-2032)
- 10.3 China Carrier Screening Tests Revenue Share by Type (2021-2032)
- 10.4 China Carrier Screening Tests Revenue by Application (2021-2032)
- 10.4.1 China Carrier Screening Tests Revenue by Application (2021-2026)
- 10.4.2 China Carrier Screening Tests Revenue by Application (2027-2032)
- 10.5 China Carrier Screening Tests Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Carrier Screening Tests Revenue (2021-2032)
- 11.2 Asia Carrier Screening Tests Revenue by Type (2021-2032)
- 11.2.1 Asia Carrier Screening Tests Revenue by Type (2021-2026)
- 11.2.2 Asia Carrier Screening Tests Revenue by Type (2027-2032)
- 11.3 Asia Carrier Screening Tests Revenue Share by Type (2021-2032)
- 11.4 Asia Carrier Screening Tests Revenue by Application (2021-2032)
- 11.4.1 Asia Carrier Screening Tests Revenue by Application (2021-2026)
- 11.4.2 Asia Carrier Screening Tests Revenue by Application (2027-2032)
- 11.5 Asia Carrier Screening Tests Revenue Share by Application (2021-2032)
- 11.6 Asia Carrier Screening Tests Revenue by Country
- 11.6.1 Asia Carrier Screening Tests Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Carrier Screening Tests Revenue by Country (2021-2026)
- 11.6.3 Asia Carrier Screening Tests Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Carrier Screening Tests Revenue (2021-2032)
- 12.2 SAMEA Carrier Screening Tests Revenue by Type (2021-2032)
- 12.2.1 SAMEA Carrier Screening Tests Revenue by Type (2021-2026)
- 12.2.2 SAMEA Carrier Screening Tests Revenue by Type (2027-2032)
- 12.3 SAMEA Carrier Screening Tests Revenue Share by Type (2021-2032)
- 12.4 SAMEA Carrier Screening Tests Revenue by Application (2021-2032)
- 12.4.1 SAMEA Carrier Screening Tests Revenue by Application (2021-2026)
- 12.4.2 SAMEA Carrier Screening Tests Revenue by Application (2027-2032)
- 12.5 SAMEA Carrier Screening Tests Revenue Share by Application (2021-2032)
- 12.6 SAMEA Carrier Screening Tests Revenue by Country
- 12.6.1 SAMEA Carrier Screening Tests Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Carrier Screening Tests Revenue by Country (2021-2026)
- 12.6.3 SAMEA Carrier Screening Tests Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst